Giovanni Caforio's most recent trade in Stryker Corp. was a trade of 560 Common Stock done . Disclosure was reported to the exchange on May 8, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Stryker | Giovanni Caforio | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 May 2025 | 560 | 3,768 (0%) | 0% | 0 | Common Stock | |
| Stryker | Giovanni Caforio | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 May 2024 | 653 | 3,208 (0%) | 0% | 0 | Common Stock | |
| Bristol-Myers Squibb | Giovanni Caforio | Director, Executive Chair of the Board | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2024 | 142,904 | 529,662 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Giovanni Caforio | Director, Executive Chair of the Board | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2024 | 142,904 | 0 | - | - | Performance Shares | |
| Bristol-Myers Squibb | Giovanni Caforio | Director, Executive Chair of the Board | Other type of transaction at price $ 0.00 per share. | 10 Mar 2024 | 49,745 | 479,917 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Giovanni Caforio | Director, Executive Chair of the Board | Payment of exercise price or tax liability using portion of securities received from the company at price $ 53.79 per share. | 10 Mar 2024 | 47,651 | 432,266 (0%) | 0% | 53.8 | 2,563,147 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Giovanni Caforio | Director, Executive Chair of the Board | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2024 | 23,817 | 400,946 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Giovanni Caforio | Director, Executive Chair of the Board | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2024 | 23,817 | 23,818 | - | - | Market Share Units | |
| Bristol-Myers Squibb | Giovanni Caforio | Director, Executive Chair of the Board | Other type of transaction at price $ 0.00 per share. | 10 Mar 2024 | 23,419 | 70,258 | - | - | Market Share Units | |
| Bristol-Myers Squibb | Giovanni Caforio | Director, Executive Chair of the Board | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2024 | 23,409 | 390,904 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Giovanni Caforio | Director, Executive Chair of the Board | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2024 | 23,409 | 0 | - | - | Market Share Units | |
| Bristol-Myers Squibb | Giovanni Caforio | Director, Executive Chair of the Board | Other type of transaction at price $ 0.00 per share. | 10 Mar 2024 | 22,214 | 44,429 | - | - | Market Share Units | |
| Bristol-Myers Squibb | Giovanni Caforio | Director, Executive Chair of the Board | Payment of exercise price or tax liability using portion of securities received from the company at price $ 53.79 per share. | 10 Mar 2024 | 10,088 | 377,129 (0%) | 0% | 53.8 | 542,634 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Giovanni Caforio | Director, Executive Chair of the Board | Payment of exercise price or tax liability using portion of securities received from the company at price $ 53.79 per share. | 10 Mar 2024 | 10,084 | 386,758 (0%) | 0% | 53.8 | 542,418 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Giovanni Caforio | Director, Executive Chair of the Board | Other type of transaction at price $ 0.00 per share. | 10 Mar 2024 | 4,104 | 396,842 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Giovanni Caforio | Director, Executive Chair of the Board | Other type of transaction at price $ 0.00 per share. | 10 Mar 2024 | 3,687 | 387,217 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Giovanni Caforio | Director, Board Chair and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 10 Oct 2023 | 440 | 367,495 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Stryker | Giovanni Caforio | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 May 2023 | 705 | 2,555 (0%) | 0% | 0 | Common Stock | |
| Stryker | Giovanni Caforio | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 May 2023 | 841 | 0 | - | - | Restricted Stock Units granted 05/04/2022 | |
| Stryker | Giovanni Caforio | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 May 2023 | 841 | 1,850 (0%) | 0% | 0 | Common Stock | |
| Bristol-Myers Squibb | Giovanni Caforio | Director, Board Chair and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2023 | 140,515 | 140,515 | - | - | Performance Shares | |
| Bristol-Myers Squibb | Giovanni Caforio | Director, Board Chair and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 140,445 | 431,381 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Giovanni Caforio | Director, Board Chair and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 140,445 | 0 | - | - | Performance Shares | |
| Bristol-Myers Squibb | Giovanni Caforio | Director, Board Chair and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2023 | 93,677 | 93,677 | - | - | Market Share Units | |
| Bristol-Myers Squibb | Giovanni Caforio | Director, Board Chair and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 65.71 per share. | 10 Mar 2023 | 80,594 | 367,935 (0%) | 0% | 65.7 | 5,295,832 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Giovanni Caforio | Director, Board Chair and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 24,793 | 260,897 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Giovanni Caforio | Director, Board Chair and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 24,793 | 0 | - | - | Market Share Units | |
| Bristol-Myers Squibb | Giovanni Caforio | Director, Board Chair and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 23,817 | 290,003 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Giovanni Caforio | Director, Board Chair and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 23,817 | 47,635 | - | - | Market Share Units | |
| Bristol-Myers Squibb | Giovanni Caforio | Director, Board Chair and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 23,407 | 276,042 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Giovanni Caforio | Director, Board Chair and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 23,407 | 23,409 | - | - | Market Share Units | |
| Bristol-Myers Squibb | Giovanni Caforio | Director, Board Chair and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 22,214 | 301,946 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Giovanni Caforio | Director, Board Chair and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 22,214 | 66,643 | - | - | Market Share Units | |
| Bristol-Myers Squibb | Giovanni Caforio | Director, Board Chair and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 65.71 per share. | 10 Mar 2023 | 17,304 | 252,635 (0%) | 0% | 65.7 | 1,137,046 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Giovanni Caforio | Director, Board Chair and CEO | Other type of transaction at price $ 0.00 per share. | 10 Mar 2023 | 17,148 | 448,529 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Giovanni Caforio | Director, Board Chair and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 65.71 per share. | 10 Mar 2023 | 14,184 | 266,186 (0%) | 0% | 65.7 | 932,031 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Giovanni Caforio | Director, Board Chair and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 65.71 per share. | 10 Mar 2023 | 14,179 | 279,732 (0%) | 0% | 65.7 | 931,702 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Giovanni Caforio | Director, Board Chair and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 65.71 per share. | 10 Mar 2023 | 11,728 | 290,936 (0%) | 0% | 65.7 | 770,647 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Giovanni Caforio | Director, Board Chair and CEO | Other type of transaction at price $ 0.00 per share. | 10 Mar 2023 | 9,042 | 269,939 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Giovanni Caforio | Director, Board Chair and CEO | Other type of transaction at price $ 0.00 per share. | 10 Mar 2023 | 4,328 | 280,370 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Giovanni Caforio | Director, Board Chair and CEO | Other type of transaction at price $ 0.00 per share. | 10 Mar 2023 | 3,908 | 293,911 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Giovanni Caforio | Director, Board Chair and CEO | Other type of transaction at price $ 0.00 per share. | 10 Mar 2023 | 718 | 302,664 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Giovanni Caforio | Director, Board Chair and CEO | Sale of securities on an exchange or to another person at price $ 74.65 per share. | 06 Feb 2023 | 240,000 | 236,104 (0%) | 0% | 74.7 | 17,916,000 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Giovanni Caforio | Director, Board Chair and CEO | Sale of securities on an exchange or to another person at price $ 69.71 per share. | 20 Sep 2022 | 25,000 | 476,104 (0%) | 0% | 69.7 | 1,742,750 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Giovanni Caforio | Director, Board Chair and CEO | Sale of securities on an exchange or to another person at price $ 71.84 per share. | 15 Sep 2022 | 50,000 | 501,104 (0%) | 0% | 71.8 | 3,592,000 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Giovanni Caforio | Director, Board Chair and CEO | Sale of securities on an exchange or to another person at price $ 74.04 per share. | 13 Jun 2022 | 30,000 | 551,104 (0%) | 0% | 74.0 | 2,221,200 | Common Stock, $0.10 par value |
| Stryker | Giovanni Caforio | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2022 | 841 | 841 | - | - | Restricted Stock Units granted 05/04/2022 | |
| Stryker | Giovanni Caforio | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 May 2022 | 693 | 693 (0%) | 0% | 0 | Common Stock | |
| Stryker | Giovanni Caforio | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 May 2022 | 693 | 0 | - | - | Restricted Stock Units granted 05/05/2021 | |
| Bristol-Myers Squibb | Giovanni Caforio | Director, Board Chair and CEO | Sale of securities on an exchange or to another person at price $ 71.52 per share. | 21 Mar 2022 | 25,000 | 581,524 (0%) | 0% | 71.5 | 1,788,000 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Giovanni Caforio | Director, Board Chair and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 21 Mar 2022 | 420 | 581,104 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Giovanni Caforio | Director, Board Chair and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2022 | 148,758 | 653,392 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Giovanni Caforio | Director, Board Chair and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2022 | 148,758 | 0 | - | - | Performance Shares | |
| Bristol-Myers Squibb | Giovanni Caforio | Director, Board Chair and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2022 | 133,285 | 133,285 | - | - | Performance Shares | |
| Bristol-Myers Squibb | Giovanni Caforio | Director, Board Chair and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 68.42 per share. | 10 Mar 2022 | 105,761 | 606,524 (0%) | 0% | 68.4 | 7,236,168 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Giovanni Caforio | Director, Board Chair and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2022 | 88,857 | 88,857 | - | - | Market Share Units | |
| Bristol-Myers Squibb | Giovanni Caforio | Director, Board Chair and CEO | Other type of transaction at price $ 0.00 per share. | 10 Mar 2022 | 58,893 | 712,285 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Giovanni Caforio | Director, Board Chair and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2022 | 24,793 | 24,793 | - | - | Market Share Units | |
| Bristol-Myers Squibb | Giovanni Caforio | Director, Board Chair and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2022 | 24,793 | 487,566 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Giovanni Caforio | Director, Board Chair and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2022 | 23,817 | 515,454 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Giovanni Caforio | Director, Board Chair and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2022 | 23,817 | 71,452 | - | - | Market Share Units | |
| Bristol-Myers Squibb | Giovanni Caforio | Director, Board Chair and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2022 | 23,407 | 502,042 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Giovanni Caforio | Director, Board Chair and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2022 | 23,407 | 46,816 | - | - | Market Share Units | |
| Bristol-Myers Squibb | Giovanni Caforio | Director, Board Chair and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2022 | 18,726 | 0 | - | - | Market Share Units | |
| Bristol-Myers Squibb | Giovanni Caforio | Director, Board Chair and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2022 | 18,726 | 472,181 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Giovanni Caforio | Director, Board Chair and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 68.42 per share. | 10 Mar 2022 | 16,466 | 478,635 (0%) | 0% | 68.4 | 1,126,604 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Giovanni Caforio | Director, Board Chair and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 68.42 per share. | 10 Mar 2022 | 13,497 | 491,637 (0%) | 0% | 68.4 | 923,465 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Giovanni Caforio | Director, Board Chair and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 68.42 per share. | 10 Mar 2022 | 13,492 | 504,634 (0%) | 0% | 68.4 | 923,123 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Giovanni Caforio | Director, Board Chair and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 68.42 per share. | 10 Mar 2022 | 9,674 | 462,773 (0%) | 0% | 68.4 | 661,895 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Giovanni Caforio | Director, Board Chair and CEO | Other type of transaction at price $ 0.00 per share. | 10 Mar 2022 | 7,535 | 495,101 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Giovanni Caforio | Director, Board Chair and CEO | Other type of transaction at price $ 0.00 per share. | 10 Mar 2022 | 3,092 | 505,134 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Giovanni Caforio | Director, Board Chair and CEO | Other type of transaction at price $ 0.00 per share. | 10 Mar 2022 | 2,672 | 518,126 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Giovanni Caforio | Director, Board Chair and CEO | Other type of transaction at price $ 0.00 per share. | 10 Mar 2022 | 266 | 472,447 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Giovanni Caforio | Director, Board Chair and CEO | Sale of securities on an exchange or to another person at price $ 67.00 per share. | 24 Feb 2022 | 30,000 | 453,455 (0%) | 0% | 67 | 2,010,000 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Giovanni Caforio | Director, Board Chair and CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Dec 2021 | 525 | 483,455 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Giovanni Caforio | Director, Board Chair and CEO | Sale of securities on an exchange or to another person at price $ 60.64 per share. | 20 Sep 2021 | 25,000 | 483,980 (0%) | 0% | 60.6 | 1,516,000 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Giovanni Caforio | Director, Chairman and CEO | Sale of securities on an exchange or to another person at price $ 68.58 per share. | 02 Aug 2021 | 20,000 | 508,980 (0%) | 0% | 68.6 | 1,371,600 | Common Stock, $0.10 par value |
| Stryker | Giovanni Caforio | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2021 | 693 | 693 | - | - | Restricted Stock Units granted 05/05/2021 | |
| Bristol-Myers Squibb | Giovanni Caforio | Director, Chairman and CEO | Sale of securities on an exchange or to another person at price $ 62.20 per share. | 22 Mar 2021 | 25,000 | 528,980 (0%) | 0% | 62.2 | 1,555,000 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Giovanni Caforio | Director, Chairman and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2021 | 142,904 | 142,904 | - | - | Performance Shares | |
| Bristol-Myers Squibb | Giovanni Caforio | Director, Chairman and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2021 | 112,343 | 0 | - | - | Performance Shares | |
| Bristol-Myers Squibb | Giovanni Caforio | Director, Chairman and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2021 | 112,343 | 603,187 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Giovanni Caforio | Director, Chairman and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2021 | 95,269 | 95,269 | - | - | Market Share Units | |
| Bristol-Myers Squibb | Giovanni Caforio | Director, Chairman and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 60.93 per share. | 10 Mar 2021 | 65,081 | 553,980 (0%) | 0% | 60.9 | 3,965,385 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Giovanni Caforio | Director, Chairman and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2021 | 24,793 | 489,572 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Giovanni Caforio | Director, Chairman and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2021 | 24,793 | 49,586 | - | - | Market Share Units | |
| Bristol-Myers Squibb | Giovanni Caforio | Director, Chairman and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2021 | 23,407 | 70,223 | - | - | Market Share Units | |
| Bristol-Myers Squibb | Giovanni Caforio | Director, Chairman and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2021 | 23,407 | 502,510 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Giovanni Caforio | Director, Chairman and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2021 | 21,443 | 0 | - | - | Market Share Units | |
| Bristol-Myers Squibb | Giovanni Caforio | Director, Chairman and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2021 | 21,443 | 466,547 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Giovanni Caforio | Director, Chairman and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2021 | 18,723 | 18,726 | - | - | Market Share Units | |
| Bristol-Myers Squibb | Giovanni Caforio | Director, Chairman and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2021 | 18,723 | 475,088 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Giovanni Caforio | Director, Chairman and CEO | Other type of transaction at price $ 0.00 per share. | 10 Mar 2021 | 15,874 | 619,061 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Giovanni Caforio | Director, Chairman and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 60.93 per share. | 10 Mar 2021 | 14,766 | 479,103 (0%) | 0% | 60.9 | 899,692 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Giovanni Caforio | Director, Chairman and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 60.93 per share. | 10 Mar 2021 | 12,104 | 490,844 (0%) | 0% | 60.9 | 737,497 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Giovanni Caforio | Director, Chairman and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 60.93 per share. | 10 Mar 2021 | 11,608 | 456,365 (0%) | 0% | 60.9 | 707,275 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Giovanni Caforio | Director, Chairman and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 60.93 per share. | 10 Mar 2021 | 8,674 | 464,779 (0%) | 0% | 60.9 | 528,507 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Giovanni Caforio | Director, Chairman and CEO | Other type of transaction at price $ 0.00 per share. | 10 Mar 2021 | 4,297 | 493,869 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Giovanni Caforio | Director, Chairman and CEO | Other type of transaction at price $ 0.00 per share. | 10 Mar 2021 | 1,635 | 473,453 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Giovanni Caforio | Director, Chairman and CEO | Other type of transaction at price $ 0.00 per share. | 10 Mar 2021 | 1,426 | 467,973 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Giovanni Caforio | Director, Chairman and CEO | Other type of transaction at price $ 0.00 per share. | 10 Mar 2021 | 438 | 502,948 (0%) | 0% | 0 | Common Stock, $0.10 par value |